aTyr Pharma Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" aTyr Pharma stock.
View analyst ratings for aTyr Pharma or view top-rated stocks.

Wall Street analysts have given aTyr Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but aTyr Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for aTyr Pharma.

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.17. aTyr Pharma had a negative net margin of 155.18% and a negative trailing twelve-month return on equity of 67.48%.
View aTyr Pharma's earnings history.

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LIFE shares have increased by 56.1% and is now trading at $4.73.
View which stocks have been most impacted by COVID-19.

aTyr Pharma's stock reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

5 brokerages have issued 12 month target prices for aTyr Pharma's shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate aTyr Pharma's stock price to reach $16.00 in the next year. This suggests a possible upside of 238.3% from the stock's current price.
View analysts' price targets for aTyr Pharma or view top-rated stocks among Wall Street analysts.

3 employees have rated aTyr Pharma CEO Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among aTyr Pharma's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to aTyr Pharma include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), Bio-Techne (TECH), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and BG Medicine (BGMD).
View all of LIFE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

aTyr Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Alyeska Investment Group L.P. (6.14%), Ikarian Capital LLC (1.87%), BlackRock Inc. (1.58%), Renaissance Technologies LLC (1.51%), Acadian Asset Management LLC (0.64%) and Dimensional Fund Advisors LP (0.40%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends for aTyr Pharma.

LIFE stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Renaissance Technologies LLC. Company insiders that have sold aTyr Pharma company stock in the last year include Jill Marie Broadfoot, John K Clarke, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma or view top insider-selling stocks.

LIFE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Alyeska Investment Group L.P., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Geode Capital Management LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, Paul Schimmel, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma or or view top insider-buying stocks.

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LIFE stock can currently be purchased for approximately $4.73.

aTyr Pharma has a market capitalization of $75.99 million and generates $10.45 million in revenue each year. The biotechnology company earns $-16,220,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

aTyr Pharma employs 40 workers across the globe.

The official website for aTyr Pharma is www.atyrpharma.com.

aTyr Pharma is headquartered at 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121.

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 731-8389 or via email at [email protected]